Inhibition of instant blood-mediated inflammatory responses by co-immobilization of sCR1 and heparin on islets

Biomaterials

Volumn 34, Issue 21, 2013, Pages 5019-5024

  Luan, Nguyen Minh ^a   Iwata, Hiroo ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cell surface modification; Heparin; Instant blood mediated inflammatory response (IBMIR); Islet transplantation; Soluble complement receptor 1 (sCR1)

Indexed keywords

CELL SURFACES; HEPARIN; INFLAMMATORY RESPONSE; ISLET TRANSPLANTATION; RECEPTOR-1;

BLOOD; CELL MEMBRANES; INSULIN; MAMMALS;

POLYSACCHARIDES;

COMPLEMENT COMPONENT C3B RECEPTOR; FIBRIN; GLUCOSE; HEPARIN; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; IN VITRO STUDY; INFLAMMATION; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION;

ANIMALS; BLOOD GLUCOSE; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; HEPARIN; IMMOBILIZED PROTEINS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, COMPLEMENT; SOLUBILITY; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VON WILLEBRAND FACTOR;

MUS;

EID: 84877018698     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.041     Document Type: Article

References (29)

1. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. NEngl J Med 2000, 343:230-238.
2. Ryan E.A., Lakey J.R., Rajotte R.V., Korbutt G.S., Kin T., Imes S., et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001, 50(4):710-719.
3. Ryan E.A., Paty B.W., Senior P.A., Bigam D., Alfadhli E., Kneteman N.M., et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060-2069.
4. Shapiro A.M. Strategies toward single-donor islets of Langerhans transplantation. Curr Opin Organ Transplant 2011, 16:627-631.
5. Barton F.B., Rickels M.R., Alejandro R., Hering B.J., Wease S., Naziruddin B., et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012, 35:1436-1445.
6. Van der Windt D.J., Bottino R., Casu A., Campanile N., Cooper D.K. Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation 2007, 14(4):288-297.
7. Bennet W., Groth C.G., Larsson R., Nilsson B., Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 2000, 105:125-133.
8. Bennet W., Sundberg B., Groth C.G., Brendel M.D., Brandhorst D., Brandhorst H., et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation?. Diabetes 1999, 48:1907-1914.
9. Nilsson B., Ekdahl K.N., Korsgren O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr Opin Organ Transplant 2011, 16(6):620-626.
10. Goto M., Tjernberg J., Dufrane D., Elgue G., Brandhorst D., Ekdahl K.N., et al. Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation 2008, 15(4):225-234.
11. Bennet W., Sundberg B., Lundgren T., Tibell A., Groth C.G., Richards A., et al. Damage to porcine islets of Langerhans after exposure to human blood invitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation 2000, 69:711-719.
12. Bennet W., Sundberg B., Song Z., Elgue G., Wennberg L., Richards A., et al. Porcine islets of Langerhans isolated from normal and hDAF transgenic pigs elicit the same acute inflammatory reaction during exposure to human blood; inhibition of the response with soluble complement receptor 1 and heparin. Transplant Proc 2000, 32(5):1065.
13. Lundgren T., Bennet W., Tibell A., Söderlund J., Sundberg B., Song Z., et al. Soluble complement receptor 1 (TP10) preserves adult porcine islet morphology after intraportal transplantation into cynomolgus monkeys. Transplant Proc 2001, 33:725.
14. Froud T., Yrizarry J.M., Alejandro R., Ricordi C. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant 2004, 13(1):55-59.
15. Luan N.M., Teramura Y., Iwata H. Immobilization of soluble complement receptor 1 on islets. Biomaterials 2011, 32:4539-4545.
16. Luan N.M., Teramura Y., Iwata H. Layer-by-layer co-immobilization of soluble complement receptor 1 and heparin on islets. Biomaterials 2011, 32:6487-6492.
17. Luan N.M., Teramura Y., Iwata H. Immobilization of the soluble domain of human complement receptor 1 on agarose-encapsulated islets for the prevention of complement activation. Biomaterials 2010, 31(34):8847-8853.
18. Luan N.M., Iwata H. Xenotransplantation of islets enclosed in agarose microcapsule carrying soluble complement receptor 1. Biomaterials 2012, 33(32):8075-8081.
19. Kato H., Inoue T., Ishii N., Murakami Y., Matsumura M., Seya T., et al. Novel simple method to purify recombinant soluble human complement receptor type 1 (sCR1) from CHO cell culture. Biotechnol Bioprocess Eng 2002, 7:67-75.
20. Teramura Y., Iwata H. Surface modification of islets with PEG-lipid for improvement of graft survival in intraportal transplantation. Transplantation 2009, 88(5):624-630.
21. Robertson R.P. Islet transplantation as a treatment for diabetes - a work in progress. NEngl J Med 2004, 350:694-705.
22. Muhlfelder T.W., Niemetz J., Kreutzer D., Beebe D., Ward P.A., Rosenfeld S.I. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. JClin Invest 1979, 63:147-150.
23. Tedesco F., Pausa M., Nardon E., Introna M., Mantovani A., Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. JExp Med 1997, 185(9):1619-1627.
24. Sims P.J., Wiedmer T. The response of human platelets to activated components of the complement system. Immunol Today 1991, 12(9):338-342.
25. Mandrup-Poulsen T., Bendtzen K., Nielsen J.H., Bendixen G., Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy 1985, 40:424-429.
26. Rabinovitch A., Suarez-Pinzon W.L., Strynadka K., Lakey J.R., Rajotte R.V. Human pancreatic islet beta-cell destruction by cytokines involves oxygen free radicals and aldehyde production. JClin Endocrinol Metab 1996, 81:3197-3202.
27. Koulmanda M., Bhasin M., Awdeh Z., Qipo A., Fan Z., Hanidziar D. The roleof TNF-α in mice with type 1- and 2- diabetes. PLoS One 2012, 7(5):e33254.
28. Stevens R.B., Ansite J.D., Mills C.D., Lokeh A., Rossini T.J., Saxena M., et al. Nitric oxide mediates early dysfunction of rat and mouse islets after transplantation. Transplantation 1996, 61(12):1740-1749.
29. Nilsson P.H., Ekdahl K.N., Magnusson P.U., Qu H., Iwata H., Ricklin D., et al. Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials 2013, 34(4):985-994.